ArticleIndian pediatrics2026
A Prospective Study on the Effect of Antiseizure Medications on the Bone Mineral Density of Children with Drug-Naïve Epilepsy.
Article in Indian pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Methodological Concerns Regarding a Prospective Study on the Effect of Antiseizure Medications on the Bone Mineral Density of Children with Drug-Naïve Epilepsy.Indian pediatrics · 2026Article
- Methodological Concerns Regarding a Prospective Study on the Effect of Antiseizure Medications on the Bone Mineral Density of Children with Drug-Naïve Epilepsy: Author's Reply.Indian pediatrics · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
Abstract
objectiveThe study aimed to evaluate the effect of antiseizure medications (ASMs) on bone health in children with drug-naive epilepsy and its associated risk factors over a one-year follow-up period.
methodsA prospective study enrolled children aged 5-15 years with drug-naïve epilepsy. At baseline and after one year of treatment with ASMs, bone mineral density (BMD) was measured by Dual energy X-ray absorptiometry (DXA), and bone metabolism markers (calcium, phosphorus, alkaline phosphatase, vitamin D, intact parathyroid hormone (i-PTH)). The primary outcome was the change in BMD after one year of treatment; secondary outcomes included BMD change in mono- and polytherapy, and changes in bone metabolism markers and risk factors for reduced BMD.
resultsSixty-five patients (40 boys) with mean (SD) age 8.6 (2.8) years completed one-year follow-up; 50 (77%) had generalized epilepsy, and 42 (65%) had an unknown etiology. 30 (46%) and 35 (54%) children received monotherapy and polytherapy, respectively. At one-year follow-up, the median (Q1, Q3) BMD was significantly lower compared to baseline [0.623, (0.540, 0.714) vs. 0.656 (0.582, 0.745); P < 0.001]. Likewise, the median (Q1, Q3) DXA Z-score was significantly lower compared to the baseline [0.20, (- 0.50, 0.60) vs. 0.50, (0.20, 0.80); P < 0.001]. At one-year, median (Q1, Q3) serum 25-OH vitamin D levels [20, (17, 27) vs. 26, (23, 33.5); P < 0.001] and i-PTH [34, (24, 56) vs. 31, (20.50, 44); P = 0.008] had significantly reduced and increased, respectively. Both mono- and polytherapy subgroups showed significant reduction in BMD, DXA z-score, and serum 25-OH vitamin D levels. Multivariate analysis identified male gender as an independent risk factor for low BMD [adjusted odds ratio 4.46, (95% CI 1.16-17.21); P = 0.030).
conclusionAntiseizure medications affect the bone health adversely in children with drug-naïve epilepsy, leading to significant reductions in BMD and altered bone metabolism markers.
Indexed as
Identifiers
41533317What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.